# BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

> **NCT07715136** · PHASE1 · RECRUITING · sponsor: **iCell Gene Therapeutics** · enrollment: 10 (estimated)

## Conditions studied

- Inflammatory Myopathy

## Interventions

- **BIOLOGICAL:** ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T

## Key facts

- **NCT ID:** NCT07715136
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715136, "BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*